These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice. Yokoyama Y; Matsuoka K; Kobayashi T; Sawada K; Fujiyoshi T; Ando T; Ohnishi Y; Ishida T; Oka M; Yamada M; Nakamura T; Ino T; Numata T; Aoki H; Sakou J; Kusada M; Maekawa T; Hibi T J Crohns Colitis; 2014 Sep; 8(9):981-91. PubMed ID: 24556083 [TBL] [Abstract][Full Text] [Related]
32. Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis. Yagi Y; Andoh A; Inatomi O; Bamba S; Tsujikawa T; Fujiyama Y; Mitsuyama K; Yoshida T J Gastroenterol; 2006 Jun; 41(6):540-6. PubMed ID: 16868801 [TBL] [Abstract][Full Text] [Related]
33. Extracorporeal leukocyte removal therapy for patients with ulcerative colitis. Kumagai M; Yamato Y; Maeda K; Nakashima E; Ushijima K; Kimura A Pediatr Int; 2007 Aug; 49(4):431-6. PubMed ID: 17587263 [TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study. Sakata Y; Iwakiri R; Amemori S; Yamaguchi K; Fujise T; Otani H; Shimoda R; Tsunada S; Sakata H; Ikeda Y; Ando T; Nakafusa Y; Fujimoto K Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):629-33. PubMed ID: 18679064 [TBL] [Abstract][Full Text] [Related]
35. Feasibility of five days of consecutive leukocytapheresis for the treatment of ulcerative colitis: a preliminary study. Tsujikawa T; Andoh A; Ogaẃa A; Sonoda A; Yagi Y; Hata K; Sasaki M; Saito Y; Fujiyama Y Ther Apher Dial; 2009 Feb; 13(1):14-8. PubMed ID: 19379165 [TBL] [Abstract][Full Text] [Related]
36. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Sawada K; Ohnishi K; Kosaka T; Chikano S; Yokota Y; Egashira A; Izawa H; Yamamura M; Amano K; Satomi M; Shimoyama T Ther Apher; 1997 Aug; 1(3):207-11. PubMed ID: 10225739 [TBL] [Abstract][Full Text] [Related]
37. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study. Sawada K; Ohdo M; Ino T; Nakamura T; Numata T; Shibata H; Sakou J; Kusada M; Hibi T Ther Apher Dial; 2016 Apr; 20(2):197-204. PubMed ID: 26771066 [TBL] [Abstract][Full Text] [Related]
38. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis. Fukunaga K; Kamikozuru K; Yokoyama Y; Hida N; Ohda Y; Takeda N; Yoshida K; Iimuro M; Kikuyama R; Kato K; Nagase K; Nakamura S; Miwa H; Matsumoto T J Clin Apher; 2011 Dec; 26(6):326-31. PubMed ID: 22083887 [TBL] [Abstract][Full Text] [Related]
39. Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis. Kanke K; Hoshino M; Tominaga K; Nakano M; Terano A; Hiraishi H Blood Purif; 2007; 25(4):370-6. PubMed ID: 17785966 [TBL] [Abstract][Full Text] [Related]
40. Leukocytapheresis therapy modulates circulating t cell subsets in patients with ulcerative colitis. Andoh A; Tsujikawa T; Inatomi O; Deguchi Y; Sasaki M; Obata H; Mitsuyama K; Fujiyama Y Ther Apher Dial; 2005 Jun; 9(3):270-6. PubMed ID: 15967005 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]